“…Fungal osteomyelitis is an example of such a pernicious manifestation, which is often preceded by trauma that disrupts the anatomic barrier to allow the pathogen to inoculate the region in question [ 1 , 4 , 7 ]. The standard goal of therapy involves meticulous, yet aggressive, surgical source control and antibiotic treatment, utilising the best available guidelines, along with infectious disease specialist support; the minimisation of joint and soft tissue dead space and balanced, multidisciplinary management of often significant medical comorbidities, including diabetes, heart disease, and rheumatological conditions, form an important adjunct to these broad objectives [ 9 – 11 ]. While L. prolificans has intrinsic resistance to all available antifungal agents, including the Azoles, Terbinafine, and Amphotericin B, several case reports and in vitro studies have shown favourable outcomes with combination antifungal therapy, notably voriconazole with Terbinafine [ 1 , 8 , 12 – 20 ].…”